Glass in the Vial: Adequan Recall Shatters Trust in Animal Pharmaceuticals

SHIRLEY, NY – July 31, 2026 – For countless owners of aging dogs and horses, the name Adequan represents relief. As the only FDA-approved drug of its kind for treating the painful grind of degenerative joint disease, it is a trusted lifeline. That trust was abruptly fractured this week as its manufacturer, American Regent, Inc. Animal Health, issued a nationwide recall for four lots of Adequan® Canine and Adequan® i.m. due to the discovery of a shocking contaminant: visible glass fibers.

The recall, initiated after the company found the particulate matter during internal testing, pulls specific lots distributed to veterinarians, wholesalers, and online pharmacies across the country between May 2024 and January 2026. While American Regent states it has received no reports of adverse events, the risk statement is chilling. Injecting a product contaminated with glass fibers can cause local irritation, swelling, infection, or painful abscesses. It is a stark betrayal of the sterile promise inherent in any injectable medicine.

This incident is more than a logistical problem of returning a faulty product. It is a profound breach of the covenant between a pharmaceutical manufacturer and the veterinarians and pet owners who depend on its products. It raises urgent questions about the integrity of the manufacturing process, the adequacy of regulatory oversight, and the systemic vulnerabilities that allow such a fundamental failure to occur.

A Pet Owner’s Dilemma

For a pet owner whose companion relies on Adequan for mobility and comfort, the news is a source of immediate anxiety. The first step is practical: check the vial's lot number. The recalled lots are 3369 and 25011 for Adequan® Canine, and 24416 and 25265P for Adequan® i.m. (for horses). American Regent’s directive is clear: stop using the product immediately.

The deeper concern is for animals who may have already received injections from these contaminated lots. The company’s risk statement focuses on immediate injection site reactions, but veterinary experts warn of more insidious possibilities. “The body’s response to a foreign material like glass can be unpredictable,” explained a veterinary pharmacologist who spoke on the condition of anonymity. “Beyond a simple abscess, there’s a risk of the body walling off the fibers, forming a chronic inflammatory mass called a granuloma. These can become persistently painful or interfere with muscle function, with symptoms emerging weeks or even months after the injection.”

This latent risk creates a difficult period of “watchful waiting” for pet owners. They are advised to monitor their animals closely for any unusual swelling, pain, heat at injection sites, or changes in behavior and to contact their veterinarian immediately with any concerns. The absence of immediate adverse event reports to the company offers little comfort, as the true toll may not be known for some time. This recall transforms a routine, therapeutic act into a source of potential harm, leaving owners to navigate a landscape of uncertainty and eroded trust.

The View from the Clinic

Veterinarians are now on the front lines of managing this crisis. Their first task is to quarantine any existing stock from the recalled lots and laboriously cross-reference patient records to identify every dog and horse that may have been treated with the contaminated product. This is followed by the difficult task of communicating the risk to anxious clients without causing undue panic.

“It’s a nightmare scenario,” a veterinarian from a multi-doctor practice shared. “Adequan is a cornerstone of our arthritis management plans. It’s not just about the risk of contamination; it’s about the disruption to care for animals in chronic pain.” This recall forces veterinarians to find alternative treatments, which may not have the same FDA-approved, disease-modifying credentials as Adequan, complicating long-term patient care.

The incident also damages the foundational trust between clinicians and the pharmaceutical industry. Veterinarians rely on the guarantee that the products they administer are safe and sterile. When that guarantee is broken so fundamentally, it casts a shadow of doubt over the entire supply chain. Every vial becomes an object of suspicion, and the burden of vigilance shifts unfairly onto the practitioner.

A Pattern of Particulates?

For those who follow the pharmaceutical industry, this recall triggers a disturbing sense of déjà vu. This is not the first time American Regent, formerly Luitpold Pharmaceuticals, has faced serious FDA scrutiny over particulate matter in its injectable drugs. A decade ago, in 2013, the same Shirley, New York, facility was at the center of a crisis that led to a severe, prolonged shortage of Adequan.

At that time, FDA inspectors found “significant” violations related to the company’s failure to prevent particulate contamination, an issue that had reportedly plagued the facility for years. The agency’s findings led to recalls and production halts, leaving veterinarians and pet owners scrambling for alternatives. The company later invested in facility modernization, promising to meet and exceed regulatory standards.

Yet here we are again. The discovery of glass fibers—a contaminant that points to a failure in the vialing or production process—suggests that the root causes of these quality control lapses may not have been fully resolved. While a 2025 recall of a different American Regent product was due to potency, this return to the issue of particulates raises serious questions about whether the company’s quality systems are as robust as they need to be. It moves the narrative from an isolated incident to a potential pattern of systemic weakness, a problem that investment and modernization have failed to definitively solve.

The U.S. Food and Drug Administration, which is aware of the recall, now faces renewed pressure. Its Center for Veterinary Medicine (CVM) is tasked with ensuring the safety of animal drugs. The agency’s response—whether it includes new inspections, warning letters, or mandated corrective actions—will be a critical test of its oversight power. For public trust to be restored, there must be a transparent investigation not only into how glass entered these vials, but also into the systems that failed to prevent it from happening again.